523 related articles for article (PubMed ID: 20945350)
1. Urinary 8-OHdG elevations in a partial lesion rat model of Parkinson's disease correlate with behavioral symptoms and nigrostriatal dopaminergic depletion.
Kikuchi Y; Yasuhara T; Agari T; Kondo A; Kuramoto S; Kameda M; Kadota T; Baba T; Tajiri N; Wang F; Tayra JT; Liang H; Miyoshi Y; Borlongan CV; Date I
J Cell Physiol; 2011 May; 226(5):1390-8. PubMed ID: 20945350
[TBL] [Abstract][Full Text] [Related]
2. Increased 8-OHdG levels in the urine, serum, and substantia nigra of hemiparkinsonian rats.
Yasuhara T; Hara K; Sethi KD; Morgan JC; Borlongan CV
Brain Res; 2007 Feb; 1133(1):49-52. PubMed ID: 17188662
[TBL] [Abstract][Full Text] [Related]
3. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
[TBL] [Abstract][Full Text] [Related]
4. 6-Hydroxydopamine-induced lesions in a rat model of hemi-Parkinson's disease monitored by magnetic resonance imaging.
Kondoh T; Bannai M; Nishino H; Torii K
Exp Neurol; 2005 Mar; 192(1):194-202. PubMed ID: 15698634
[TBL] [Abstract][Full Text] [Related]
5. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
Lee EY; Lee JE; Park JH; Shin IC; Koh HC
Toxicol Lett; 2012 Sep; 213(3):332-44. PubMed ID: 22842585
[TBL] [Abstract][Full Text] [Related]
6. Regulation of GAP-43 protein and mRNA in nigrostriatal dopaminergic neurons after the partial destruction of dopaminergic terminals with intrastriatal 6-hydroxydopamine.
Iwata SI; Nomoto M; Fukuda T
Synapse; 2001 Jan; 39(1):16-22. PubMed ID: 11071705
[TBL] [Abstract][Full Text] [Related]
7. Parkinsonian motor deficits are reflected by proportional A9/A10 dopamine neuron degeneration in the rat.
Moore AE; Cicchetti F; Hennen J; Isacson O
Exp Neurol; 2001 Dec; 172(2):363-76. PubMed ID: 11716560
[TBL] [Abstract][Full Text] [Related]
8. Dopaminergic and behavioral correlates of progressive lesioning of the nigrostriatal pathway with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Goldberg NR; Haack AK; Lim NS; Janson OK; Meshul CK
Neuroscience; 2011 Apr; 180():256-71. PubMed ID: 21335067
[TBL] [Abstract][Full Text] [Related]
9. Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons.
Porritt MJ; Batchelor PE; Howells DW
Exp Neurol; 2005 Mar; 192(1):226-34. PubMed ID: 15698637
[TBL] [Abstract][Full Text] [Related]
10. Developing a preclinical model of Parkinson's disease: a study of behaviour in rats with graded 6-OHDA lesions.
Truong L; Allbutt H; Kassiou M; Henderson JM
Behav Brain Res; 2006 Apr; 169(1):1-9. PubMed ID: 16413939
[TBL] [Abstract][Full Text] [Related]
11. Partial dopamine loss enhances activated caspase-3 activity: differential outcomes in striatal projection systems.
Ariano MA; Grissell AE; Littlejohn FC; Buchanan TM; Elsworth JD; Collier TJ; Steece-Collier K
J Neurosci Res; 2005 Nov; 82(3):387-96. PubMed ID: 16180225
[TBL] [Abstract][Full Text] [Related]
12. Time-course of nigrostriatal damage, basal ganglia metabolic changes and behavioural alterations following intrastriatal injection of 6-hydroxydopamine in the rat: new clues from an old model.
Blandini F; Levandis G; Bazzini E; Nappi G; Armentero MT
Eur J Neurosci; 2007 Jan; 25(2):397-405. PubMed ID: 17284180
[TBL] [Abstract][Full Text] [Related]
13. Ginkgo biloba affords dose-dependent protection against 6-hydroxydopamine-induced parkinsonism in rats: neurobehavioural, neurochemical and immunohistochemical evidences.
Ahmad M; Saleem S; Ahmad AS; Yousuf S; Ansari MA; Khan MB; Ishrat T; Chaturvedi RK; Agrawal AK; Islam F
J Neurochem; 2005 Apr; 93(1):94-104. PubMed ID: 15773909
[TBL] [Abstract][Full Text] [Related]
14. Alteration of dopaminergic markers in gastrointestinal tract of different rodent models of Parkinson's disease.
Tian YM; Chen X; Luo DZ; Zhang XH; Xue H; Zheng LF; Yang N; Wang XM; Zhu JX
Neuroscience; 2008 May; 153(3):634-44. PubMed ID: 18420351
[TBL] [Abstract][Full Text] [Related]
15. Cystatin C prevents degeneration of rat nigral dopaminergic neurons: in vitro and in vivo studies.
Xu L; Sheng J; Tang Z; Wu X; Yu Y; Guo H; Shen Y; Zhou C; Paraoan L; Zhou J
Neurobiol Dis; 2005 Feb; 18(1):152-65. PubMed ID: 15649706
[TBL] [Abstract][Full Text] [Related]
16. Delivery of a GDNF gene into the substantia nigra after a progressive 6-OHDA lesion maintains functional nigrostriatal connections.
Kozlowski DA; Connor B; Tillerson JL; Schallert T; Bohn MC
Exp Neurol; 2000 Nov; 166(1):1-15. PubMed ID: 11031079
[TBL] [Abstract][Full Text] [Related]
17. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease.
Zheng JS; Tang LL; Zheng SS; Zhan RY; Zhou YQ; Goudreau J; Kaufman D; Chen AF
Brain Res Mol Brain Res; 2005 Mar; 134(1):155-61. PubMed ID: 15790539
[TBL] [Abstract][Full Text] [Related]
18. Biochemical alteration in cerebrospinal fluid precedes behavioral deficits in Parkinsonian rats induced by 6-hydroxydopamine.
Lin JW; Shih CM; Chen YC; Lin CM; Tsai JT; Chiang YH; Shih R; Chiu PL; Hung KS; Yeh YS; Wei L; Chiu WT; Yang LY
Surg Neurol; 2009 Dec; 72 Suppl 2():S55-65; discussion S65. PubMed ID: 19944827
[TBL] [Abstract][Full Text] [Related]
19. Moderate degeneration of nigral neurons after repeated but not after single intrastriatal injections of low doses of 6-hydroxydopamine in mice.
Richter F; Hamann M; Richter A
Brain Res; 2008 Jan; 1188():148-56. PubMed ID: 18035334
[TBL] [Abstract][Full Text] [Related]
20. Ketogenic diet protects dopaminergic neurons against 6-OHDA neurotoxicity via up-regulating glutathione in a rat model of Parkinson's disease.
Cheng B; Yang X; An L; Gao B; Liu X; Liu S
Brain Res; 2009 Aug; 1286():25-31. PubMed ID: 19559687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
